Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
暂无分享,去创建一个
A. Oza | M. Friedlander | N. Colombo | G. Scambia | H. Denys | B. Ataseven | G. Sonke | T. Huzarski | Nanda Aryal | A. Clamp | Chee Khoon Lee | E. Lowe | R. Penson | E. Pujade-Lauraine | S. Mahner | C. Dubot | K. Fujiwara | F. Trillsch | A. Casado | R. Asher | A. Amit | C. Lee
[1] A. Oza,et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. , 2021, The Lancet. Oncology.
[2] I. Ray-Coquard,et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. , 2020, The Lancet. Haematology.
[3] A. Oza,et al. Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons? , 2020, Cancers.
[4] R. Wenham,et al. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Mouret-Reynier,et al. EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study. , 2019, Journal of Clinical Oncology.
[6] A. Reuss,et al. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883) , 2019, Journal of Medical Genetics.
[7] A. Tinker,et al. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. , 2019, Gynecologic oncology.
[8] G. Lenhart,et al. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States. , 2018, Gynecologic oncology.
[9] V. Gebski,et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. , 2018, The Lancet. Oncology.
[10] K. Moore,et al. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. , 2017, Gynecologic oncology.
[11] James X. Sun,et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[12] Val Gebski,et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.
[13] W. Chung,et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.
[14] A. Reuss,et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] M. Lux,et al. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO) , 2016, Journal of Cancer Research and Clinical Oncology.
[16] D. Matei,et al. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer , 2016, British Journal of Cancer.
[17] H. Cohen,et al. NCCN Guidelines ® Insights Older Adult Oncology, Version 2.2016 Featured Updates to the NCCN Guidelines , 2016 .
[18] Ignace Vergote,et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.
[19] C. U. Uyl‐de Groot,et al. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[20] J. Daurès,et al. Under-treatment of elderly patients with ovarian cancer: a population based study , 2015, BMC Cancer.
[21] A. Abernethy,et al. Patient preferences in advanced or recurrent ovarian cancer , 2014, Cancer.
[22] D. Matei,et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[23] R. Zeillinger,et al. Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium , 2013, Journal of Ovarian Research.
[24] John Brazier,et al. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[25] D. Matei,et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.
[26] P. Harter,et al. Treatment of Elderly Ovarian Cancer Patients in the Context of Controlled Clinical Trials: A Joint Analysis of the AGO Germany Experience , 2012, Oncology Research and Treatment.
[27] D. Katsaros,et al. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. , 2009, Critical reviews in oncology/hematology.
[28] G. Vlastos,et al. Older female cancer patients: importance, causes, and consequences of undertreatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] S. Mayne,et al. Myelodysplastic syndromes , 2007, Cancer.
[30] S. Loibl,et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.